EU and AstraZeneca Agreed For Coronavirus Vaccine

EU and AstraZeneca Agreed For Coronavirus Vaccine

The EU and AstraZeneca reached an agreement for a coronavirus vaccine. The European Union announced that it has agreed to purchase the potential vaccine developed by the pharmaceutical company AstraZeneca in order to combat the coronavirus epidemic. The European Union (EU) Commission stated that within the framework of the possible vaccine pre-purchase strategy developed to completely end the coronavirus epidemic, the first agreement was made with the pharmaceutical factory AstraZeneca, headquartered in Cambridge, England. It was stated that 300 million doses will be taken on behalf of EU member countries after the vaccine developed was proven to be safe and effective against Kovid-19 disease caused by coronavirus, and it was stated that the contract included the option of receiving 100 million doses of additional vaccine. In the statement made by the EU, it was stated that preliminary negotiations were made for similar agreements with Sanofi-GSK and Johnson & Johnson, who continue their vaccination studies. The potential vaccine "ChAdOx1 nCoV-19", developed in collaboration with the Oxford Vaccine Group and the Jenner Institute and whose production license was acquired by the British-Swedish pharmaceutical company AstraZeneca, was tested on humans in Brazil in late June.